Search - tctmd.com

Displaying 801 - 820 of 1041

Sort: Relevancy | Date

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

News Daily News

FDA Tackles Regulatory, Scientific Issues With Point-of-Care Coagulation Monitoring Devices

Todd Neale

March 24, 2016

News Daily News

Good Guys, Bad Guys, or Just Big Money? The Push to Link Patient-Claims Data to Device Outcomes

Shelley Wood

March 17, 2016

News Daily News

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Michael O'Riordan

March 09, 2016

News Daily News

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

Michael O'Riordan

March 07, 2016

News Daily News

‘Smoker’s Paradox’ Eliminated With Double Dose of Clopidogrel: GRAVITAS Analysis

Michael O'Riordan

February 28, 2016

News Conference News ISC 2016

To Anticoagulate or Not? Debating Secondary Stroke Prevention in an A-fib Patient With Microbleeds

Michael O'Riordan

February 23, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Daily News

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Michael O'Riordan

February 15, 2016

News Daily News

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Michael O'Riordan

February 15, 2016

News Daily News

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Michael O'Riordan

February 15, 2016

News Daily News

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

Caitlin E. Cox

February 08, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Daily News

‘Negative’ Atherosclerotic Imaging Results Shift 10-Year CVD Risk Downward: MESA Analysis

Michael O'Riordan

January 28, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Industry News

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

January 21, 2016

Advertisement

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

FDA Tackles Regulatory, Scientific Issues With Point-of-Care Coagulation Monitoring Devices

Good Guys, Bad Guys, or Just Big Money? The Push to Link Patient-Claims Data to Device Outcomes

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

‘Smoker’s Paradox’ Eliminated With Double Dose of Clopidogrel: GRAVITAS Analysis

To Anticoagulate or Not? Debating Secondary Stroke Prevention in an A-fib Patient With Microbleeds

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

TCTMD’s Top 10 Most Popular Stories for January 2016

‘Negative’ Atherosclerotic Imaging Results Shift 10-Year CVD Risk Downward: MESA Analysis

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content